Last $64.79 USD
Change Today -0.59 / -0.90%
Volume 24.5K
CBPO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

china biologic products inc (CBPO) Snapshot

Open
$65.71
Previous Close
$65.38
Day High
$65.71
Day Low
$64.00
52 Week High
11/24/14 - $71.13
52 Week Low
01/6/14 - $26.66
Market Cap
1.6B
Average Volume 10 Days
38.6K
EPS TTM
$2.57
Shares Outstanding
24.7M
EX-Date
--
P/E TM
25.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for CHINA BIOLOGIC PRODUCTS INC (CBPO)

Related News

No related news articles were found.

china biologic products inc (CBPO) Related Businessweek News

No Related Businessweek News Found

china biologic products inc (CBPO) Details

China Biologic Products, Inc., a biopharmaceutical company, is engaged in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers. It offers human albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also offers human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human albumin and human immunoglobulin for intravenous injection (IVIG) products for original immunoglobulin deficiency, secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides injection for the treatment of original and secondary T-cell deficiency syndromes, auto-immune deficiency diseases, and a range of cell immunity deficiency diseases, as well as assists in the treatment for tumors. In addition, it provides human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; human tetanus immunoglobulin for the prevention and therapy of tetanus; placenta polypeptide that is used for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative heating; and Human coagulation factor VIII for the treatment of coagulopathie, such as hemophilia A. The company’s products under development comprise human prothrombin complex concentrate; human hepatitis B immunoglobulin (PH4) for intravenous injection; human fibrinogen; Varicella hyperimmune globulins; immune globulin intravenous, Caprylate/Chromatography virus filtration; and human antithrombin III. It distributes its products directly or through distributors. The company is headquartered in Beijing, the People's Republic of China.

1,467 Employees
Last Reported Date: 03/12/14

china biologic products inc (CBPO) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: $878.7K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $328.7K
Corporate Vice President
Total Annual Compensation: $265.5K
Senior Corporate Vice President and Corporate...
Total Annual Compensation: $244.2K
Corporate Vice President
Total Annual Compensation: $169.3K
Compensation as of Fiscal Year 2013.

china biologic products inc (CBPO) Key Developments

China Biologic Products, Inc. Appoints Joseph Chow as an Independent Director

On November 3, the Board of Directors of China Biologic Products, Inc. appointed Mr. Joseph Chow as an independent director of the company, effective from the same date thereof. Mr. Chow has over 20 years of experience in corporate finance, financial advisory and management and has held senior executive and managerial positions in various public and private companies. Mr. Chow was recently a managing director of Moelis and Company and was previously a managing director at Goldman Sachs (Asia) LLP. Prior to that, he served as an independent financial consultant, as chief financial officer of Harbor Networks Limited, and as chief financial officer of China Netcom (Holdings) Company Limited. Prior to that, Mr. Chow served as the director of strategic planning of Bombardier Capital, Inc., as vice president of international operations of Citigroup and as the corporate auditor of GE Capital. Mr. Chow currently sits on the board as a director for China Lodging Group, Limited and an independent non-executive director for Intime Department Store (Group) Co. Ltd.

China Biologic Products, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Earnings Guidance for the Year 2014

China Biologic Products, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported sales of $68,923,830 compared to $53,152,141 a year ago. Income from operations was $34,624,129 compared to $23,162,818 a year ago. Earnings before income tax expense were $35,214,403 compared to $24,819,004 a year ago. Net income attributable to the company was $20,060,066 or $0.76 diluted per share compared to $14,696,023 or $0.53 diluted per share a year ago. Adjusted net income attributable to the company - non GAAP was $21,236,986 or $0.81 diluted per share compared to $15,549,559 or $0.56 diluted per share a year ago. Excluding the foreign currency impact, the increase in sales was primarily attributable to the sales volume increases in IVIG and placenta polypeptide. For the nine months period, the company reported sales of $185,264,391 compared to $160,764,396 a year ago. Income from operations was $91,476,097 compared to $74,456,523 a year ago. Earnings before income tax expense were $95,762,988 compared to $78,061,560 a year ago. Net income attributable to the company was $58,058,692 or $2.24 diluted per share compared to $45,773,809 or $1.64 diluted per share a year ago. Net cash provided by operating activities was $64,107,926 compared to $58,459,957 a year ago. The increase in net cash provided by operating activities was mainly due to the impact from the changes in net income and accounts receivable. Payment for property, plant and equipment was $13,925,010 compared to $17,076,459 a year ago. Payment for intangible assets and land use rights was $2,834,220 compared to $1,141,197 a year ago. Adjusted net income attributable to the company - non GAAP was $60,831,362 or $2.34 diluted per share compared to $49,351,104 or $1.77 diluted per share a year ago. For the full year of 2014, the company expects the revenue to increase from $230-$240 million to $240-$245 million, an 18%-20% increase over the prior year, and the non-GAAP adjusted net income to increase from $67-$69 million to $76-$78 million, excluding the impact of a potential one-time bad-debt provision of approximately $5 million (of which approximately $3.5 million is attributable to the Company) to be made in connection with an employee housing development project in Shandong.

China Biologic Products, Inc. to Report Q3, 2014 Results on Nov 05, 2014

China Biologic Products, Inc. announced that they will report Q3, 2014 results at 5:00 PM, China Standard Time on Nov 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBPO:US $64.79 USD -0.59

CBPO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hualan Biological Engineering Inc CNY34.35 CNY +0.34
Jiangxi Boya Bio-Pharmaceutical Co Ltd CNY65.70 CNY -0.12
Shanghai RAAS Blood Products Co Ltd CNY44.90 CNY +0.22
View Industry Companies
 

Industry Analysis

CBPO

Industry Average

Valuation CBPO Industry Range
Price/Earnings 25.5x
Price/Sales 7.0x
Price/Book 8.2x
Price/Cash Flow 23.9x
TEV/Sales 5.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHINA BIOLOGIC PRODUCTS INC, please visit www.chinabiologic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.